Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    September 2025
  1. BLINKA S, Yu EY
    Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.
    Clin Cancer Res. 2025 Sep 9. doi: 10.1158/1078-0432.CCR-25-2546.
    >> Share

    August 2025
  2. OWIREDU J, Ersoy-Fazlioglu B, Poluben L, Calagua C, et al
    Increased ErbB2 signaling is an early adaptation to androgen signaling inhibition and persists in castration resistant prostate cancer.
    Clin Cancer Res. 2025 Aug 12. doi: 10.1158/1078-0432.CCR-22-3683.
    >> Share

  3. NAYAK S, Norris JD, Ammirante M, Rychak E, et al
    Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0471.
    >> Share

  4. JIAO J, Ma S, Wu P, Song X, et al
    Transrectal Ultrasound-Guided Prostate Biopsy With and Without PSMA PET-Targeted Prostate Biopsy for Prostate Cancer Diagnosis.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0320.
    >> Share

    July 2025
  5. GRAHAM LS, Yu EY
    Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer.
    Clin Cancer Res. 2025 Jul 31. doi: 10.1158/1078-0432.CCR-25-2359.
    >> Share

  6. AGGARWAL R, Rottey S, Bernard-Tessier A, Mellado B, et al
    Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.
    Clin Cancer Res. 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1211.
    >> Share

  7. MAGUIRE WF, Chi DC, Agrawal S, Joeng HK, et al
    FDA Approval Summary: Niraparib Plus Abiraterone Acetate Fixed Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Jul 17. doi: 10.1158/1078-0432.CCR-25-0883.
    >> Share

  8. PATEL RB, Adler SS, Escorcia FE
    Size Matters: Superior Efficacy of alpha Particle Radioimmunotherapy in Micrometastases versus Macrometastases.
    Clin Cancer Res. 2025;31:2847-2849.
    >> Share

  9. SHEN F, Smith R, McDevitt T, Menard K, et al
    Human kallikrein 2: A novel lineage-specific surface target in prostate cancer.
    Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-25-0950.
    >> Share

    June 2025
  10. HAGE CHEHADE C, Graf RP, Ozay ZI, Gebrael G, et al
    Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer.
    Clin Cancer Res. 2025 Jun 16. doi: 10.1158/1078-0432.CCR-25-1178.
    >> Share

    May 2025
  11. DEV H, Linch M, Narahari K, Milne-Clark T, et al
    Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib +/- Degarelix in Primary Prostate Cancer.
    Clin Cancer Res. 2025 May 13:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-1304.
    >> Share

  12. ARAFA AT, Yadav S, Marshall CH, Mauer E, et al
    Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.
    Clin Cancer Res. 2025;31:1730-1745.
    >> Share

    April 2025
  13. WERNECK GOMES H, Lister NL, Keerthikumar S, Niranjan B, et al
    p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer.
    Clin Cancer Res. 2025 Apr 25. doi: 10.1158/1078-0432.CCR-24-3848.
    >> Share

  14. SHAH K, Secrest MH, Zhou W, Wang S, et al
    Clinical Context Shapes the Relationship Between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
    Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1812.
    >> Share

  15. KISHAN AU, McGreevy K, Valle L, Steinberg M, et al
    Validation and Derivation of MicroRNA-based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.
    Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3951.
    >> Share

    March 2025
  16. MCNEVIN CS, Keogh A, Mohammed Nur M, McGovern B, et al
    Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.
    Clin Cancer Res. 2025 Mar 19:OF1-OF8. doi: 10.1158/1078-0432.CCR-24-1210.
    >> Share

  17. ZHANG L, Teng PC, Cavassani KA, Wang J, et al
    Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer.
    Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-3660.
    >> Share

  18. HWANG J, Likasitwatanakul P, Deshmukh SK, Wu S, et al
    Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes.
    Clin Cancer Res. 2025;31:936-948.
    >> Share

    February 2025
  19. BJARTELL A, Krzyzanowska A, Liu VYT, Tierney M, et al
    Validation of a digital pathology-based multimodal artificial intelligence biomarker in a prospective, real-world prostate cancer cohort treated with prostatectomy.
    Clin Cancer Res. 2025 Feb 21. doi: 10.1158/1078-0432.CCR-24-3656.
    >> Share

  20. GALSKY MD, Autio KA, Cabanski CR, Wentzel K, et al
    Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693.
    >> Share

  21. BIDKAR AP, Peter R, Wadhwa A, Bobba KN, et al
    Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
    Clin Cancer Res. 2025 Feb 13. doi: 10.1158/1078-0432.CCR-24-2850.
    >> Share

    January 2025
  22. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    >> Share

  23. ANDREWS J, Kim Y, Horjeti E, Arafa A, et al
    PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate Cancer Analysis from the STOMP-like and ORIOLE trial cohorts.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-3027.
    >> Share

  24. WELTI J, Bogdan D, Figueiredo I, Coleman I, et al
    NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386.
    >> Share

    November 2024
  25. HAFFNER MC, Morris MJ, Ding CC, Sayar E, et al
    Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
    Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2061.
    >> Share

  26. WINQUIST E, Hotte SJ, Chi K, Sridhar S, et al
    Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612.
    >> Share

  27. NAWFAL R, El Hajj Chehade R, Berchuck JE
    Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
    Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-2849.
    >> Share

    October 2024
  28. STOPSACK KH, Vijai J, Conry M, Berchuck JE, et al
    Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer.
    Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-2483.
    >> Share

    September 2024
  29. ISAACSSON VELHO P, Bastos DA, Saint'ana PT, Rigatti B, et al
    Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.
    Clin Cancer Res. 2024 Sep 27. doi: 10.1158/1078-0432.CCR-24-1595.
    >> Share

  30. CHOU J, Robinson TM, Egusa EA, Lodha R, et al
    Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
    Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-23-3785.
    >> Share

  31. JENSEN JL, Bobek O, Chan ICC, Miller BC, et al
    Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
    Clin Cancer Res. 2024 Sep 17:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0803.
    >> Share

  32. DALLOS MC, Obradovic AZ, McCann P, Chowdhury N, et al
    Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-0060.
    >> Share

    August 2024
  33. CHAUHAN PS, Alahi I, Sinha S, Ledet EM, et al
    Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-1658.
    >> Share

  34. HUSSAIN M, Kocherginsky M, Agarwal N, Adra N, et al
    Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
    Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-1402.
    >> Share

  35. NGUYEN CB, Reimers MA, Perera C, Abida W, et al
    Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Clin Cancer Res. 2024;30:3200-3210.
    >> Share

    July 2024
  36. SWEENEY CJ, Petry R, Xu C, Childress M, et al
    Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-1096.
    >> Share

  37. LENIS AT, Ravichandran V, Brown S, Alam SM, et al
    Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.
    Clin Cancer Res. 2024 Jul 1. doi: 10.1158/1078-0432.CCR-23-3403.
    >> Share

    April 2024
  38. APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al
    A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740.
    >> Share

  39. ARCHER S, Brailey PM, Song M, Bartlett PD, et al
    CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
    Clin Cancer Res. 2024;30:1595-1606.
    >> Share

  40. SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al
    Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
    Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746.
    >> Share

  41. CHO H, Byun SS, Son NH, Chung JI, et al
    Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
    Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083.
    >> Share

    March 2024
  42. DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al
    A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
    Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636.
    >> Share

  43. AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al
    A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436.
    >> Share

  44. ANSELMINO N, Labanca E, Shepherd PDA, Dong J, et al
    Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.
    Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-23-2438.
    >> Share

    February 2024
  45. VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al
    ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
    Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161.
    >> Share

  46. DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al
    A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978.
    >> Share

    January 2024
  47. HALABI S, Guo S, Park JJ, Nanus DM, et al
    The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017.
    >> Share

  48. ABIDA W, Hahn AW, Shore N, Agarwal N, et al
    Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing on Enzalutamide.
    Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508.
    >> Share

    September 2023
  49. CHAUDAGAR K, Hieromnimon HM, Kelley A, Labadie B, et al
    Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis.
    Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016